

October 31, 2005

**VIA COURIER**

Allan Seidenfeld, President  
INSCYTE Corporation  
2 Berkeley Street, Suite 403  
Toronto, Ontario  
M5A 2W3

Dear Dr. Seidenfeld:

**Re: PHIPA-Prescribed Registry – Review and Approval**

Pursuant to section 13(2) of Ontario Regulation 329/04, an organization that has been designated a “prescribed person” under section 39(1)(c) of *Personal Health Information Protection Act, 2004 (PHIPA)*, must have its practices and procedures with respect to privacy and the protection of personal health information, approved by my office prior to November 1, 2005.

Section 13(2) provides:

(2) A person that is a prescribed person for the purposes of clause 39 (1) (c) of the Act shall put in place practices and procedures approved by the Commissioner to protect the privacy of the individuals whose personal health information it receives and to maintain the confidentiality of the information, except that the practices and procedures are not required to be approved by the Commissioner until the first anniversary of the day that section 45 of the Act comes into force.

.../2



My office has completed its detailed review of the practices and procedures of the prescribed person, the INSCYTE Corporation in respect of CytoBase, and effective October 31, 2005, these practices and procedures have been approved.

Thank you for your full cooperation throughout the review process.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Ann Cavoukian". The signature is fluid and cursive, with a large initial "A" and a long, sweeping underline.

Ann Cavoukian, Ph.D.  
Commissioner

cc: Jack Golabek, Privacy Officer, INSCYTE Corporation  
Peter Brueckner, CEO, AIM